ERT, the leading provider of best-in-class technology and services for the successful execution of clinical trials, today announced that, following extensive external and internal assessment, it is launching its new branding. Formerly eResearchTechnology, Inc., the company has adopted an entirely new image and character for the company following staff feedback and customer affirmation of its core values. The unrivalled business found that both customers and employees expect and receive a commitment from ERT that it will get the job done, and right. ERT is a dynamic and proactive organization that is committed to redefining and setting new standards of how clinical trials are successfully conducted.
This new brand strategy brings an enhanced visual identity to market as well as sharpened product positioning, a new web site, messaging and corporate collateral. As part of its new branding commitment ERT has introduced a new platform of products and services in the clinical trials arena to its customers worldwide. This consists of four sub-brands for ERT’s industry-leading products and services: Cardiac Safety Solutions; EDC Solutions; ePRO Solutions and ERT Clinical Research Consulting Group. Cardiac Safety, EDC and ePRO Solutions are founded upon the company’s innovative technology platform – EXPERT. EXPERT is a robust, secure and validated clinical-research workflow-processing system that powers centralized electronic data collection, data management and information exchange. All of ERT’s solutions are supported by cross-functional teams operating within its SOP-driven, Project Assurance methodology that delivers exceptional performance metrics and customer satisfaction.
Originally founded in 1972 as Cardio Data Systems, the company moved its headquarters to Philadelphia in 1993 and following a series of acquisitions formed the company eResearch Technology Inc. in 2000. “eResearchTechnology was known as a company that offered unparalleled service and comprehensive and reliable solutions which help companies bring safe products to market,” commented Michael McKelvey, President and CEO of ERT. “Our new brand identity reflects ERT’s dynamism and passion while continuing to instill the confidence and trust that the industry has in our products and services. We see the change as a move forward in establishing the company as the most experienced and reliable partner in products and services for clinical trials. ERT gets the job done right.”
For further information on ERT and its technology and services please call +1 215 972 0420.
About eResearchTechnology, Inc. (ERT)
Based in Philadelphia, Pa, ERT (ert.com) is a provider of technology and services to the biopharmaceutical and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2008 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.